- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Public Companies
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Beverly H. Lorell, M.D.
Events 18 results
Webinar
September 9, 2021
14th Annual King & Spalding Medical Device Summit
Webinar
June 15, 2021
Real-World Evidence: The Evolving Landscape for FDA and EU Decision-Making About Drugs, Biologics, and Medical Devices
Webinar
March 16, 2021
The New Intensified Scrutiny and Enforcement of FDA-Regulated Clinical Trials
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Webinar
April 3, 2020
Clinical Trials During the COVID-19 Pandemic and Recent Court Decision on ClinicalTrials.gov
Webinar
May 16, 2019
Just Around the Corner: FDA’s Proposed Rule Would Make Major Changes in Requirements for U.S. Mammography Facilities
Webinar
May 31, 2017
ClinicalTrials.gov – Navigating the New Rule and the Expansion of Public Disclosure of Your Clinical Trial Data
Conference
January 12, 2017
An Introduction to the 21st Century Cures Act
Conference
November 15, 2016
9th Annual King & Spalding Pharmaceutical University
Conference
September 8, 2016
The Conundrum of Medicinal Marijuana: Implications for Healthcare Providers and Pharmaceutical Companies
Conference
July 20, 2016
The New FDA Approach for Expanded Access to Investigational Drugs
Conference
January 20, 2016
The New Era of Informed Consent, including Biospecimens and Privacy